© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
September 19, 2021
There was limited clinical activity with the combination in patients with HRD-negative tumors.
February 15, 2021
The combination of the anti–PD-1 immunotherapy and the multikinase inhibitor also extended progression-free survival in the phase 3 KEYNOTE-581/CLEAR trial (Study 307).